

## Daily Program Schedule

### Wednesday, September 25, 2024

8:00-9:00	<b>OPENING CEREMONY</b> <b>P D V</b>	Pavilion 3
8:00-8:05	Welcome	
8:05-8:30	Pioneers in Myeloma	
8:30-9:00	President's Address	Philippe Moreau
9:00-9:30	<b>KEYNOTE</b> <b>P D V</b>	Pavilion 3
	<b>AI in Multiple Myeloma: Recent Findings and Opportunities</b>	Anant Madabhushi
9:30-10:00	<b>BREAK</b>	Exhibit Hall, Pavilion 3
10:00-11:30	<b>PRECURSOR DISEASE</b> <b>P D V</b>	Pavilion 3
	<i>Chair: Sagar Lonial, Co-chair: Maria-Victoria Mateos</i>	
10:00-10:10	Approaches to Risk Stratification in High Risk Myeloma	Irene Ghobrial
10:10-10:20	What we have learnt from iSTOPMM?	Sigurdur Kristinsson
10:20-10:30	Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention	Madhav Dhodapkar
10:30-10:40	Current approach for the management of SMM	Vincent Rajkumar
10:40-11:00	Future Directions and Challenges	Maria-Victoria Mateos
11:00-11:30	Round Table discussion	Session faculty + Elena Zamagni
11:30-12:30	<b>ABSTRACT SESSION 1</b> <b>P D</b>	101 A1-A2
	<i>Co-chairs: Natalie Callander and Sergio Giralt</i>	
11:30-12:30	<b>ABSTRACT SESSION 2</b> <b>P D</b>	101 B1-B2
	<i>Co-chairs: Niccolo Bolli and Michel Delforge</i>	
12:30-13:30	<b>LUNCH AND POSTERS</b>	Exhibit Hall, Pavilion 3

13:30-15:00	<b>INDUSTRY SYMPOSIUM SUPPORTED BY BRISTOL MYERS SQUIBB</b> P D V <b>Role of immune strategies in consolidation and maintenance</b> <i>Chair: Joseph Mikhael</i>	Pavilion 3
13:30-13:35	Introduction of the faculty members and objectives of the symposium	Joseph Mikhael
13:35-13:50	Understanding the unmet needs in a post ASCT NDMM setting	Fredrik Schjesvold
13:50-14:05	Fresh insights from the latest clinical trial data in NDMM post ASCT setting	Roberto Mina
14:05-14:30	Optimizing outcomes of earlier line patients treated with CAR T cell therapy • Exploring debulking strategies prior to CAR T consolidation • Exploring new & effective combination/maintenance strategies	Krina Patel Luciano Costa
14:30-15:00	Panel Discussion with Summary & Close	
15:00-16:30	<b>NEWLY DIAGNOSED</b> P D V <i>Chair: Jesus San Miguel, Co-chair: Philippe Moreau</i>	Pavilion 3
15:00-15:10	Induction therapy in Transplant Eligible Patients	Francesca Gay
15:10-15:20	What is the best consolidation/maintenance?	Ajay Nooka
15:20-15:30	Is there any genomic and immune signatures predicting outcome in NDMM?	Nizar Bahlis
15:30-15:40	Management of NDMM in low income countries	Dorotea Fantl
15:40-15:50	Transplant Ineligible Patients	Salomon Manier
15:50-16:05	Future Directions and Challenges	Philippe Moreau
16:05-16:30	Round Table discussion	Session faculty + Hartmut Goldschmidt
16:30-17:00	<b>BREAK</b>	Exhibit Hall, Pavilion 3
17:00-18:00	<b>MRD IS AN END POINT: OUR SUCCESS STORY</b> P D V <i>Co-chairs: Brian Durie and Jean-Luc Harousseau</i>	Pavilion 3
17:00-17:10	Explanation of ODAC	Shaji Kumar
17:10-17:30	Discussion	Nikhil Munshi and Jesus San Miguel
17:30-18:00	Audience Q&A	Session faculty + Ola Landgren
18:00-19:00	<b>POSTER SESSION</b> P <i>Discussants: Rafat Abonour, Diana Cirstea, P. Joy Ho, Andrew Yee</i>	Exhibit Hall, Pavilion 3

# Thursday, September 26, 2024

7:00-8:00	<b>MEET THE EXPERT</b> <b>P</b>	
203C	Role of Transplant	Morie Gertz and Heinz Ludwig
204A	Frailty-adapted therapy	Gordon Cook and Ashley Rosko
204B	Extramedullary disease/PCI	Laura Rosiñol and Yael Cohen
204C	How to manage 2L+ in the near future?	Rafael Fonseca and Leo Rasche
8:00-9:00	<b>INDUSTRY SYMPOSIUM SUPPORTED BY GSK</b> <b>P D V</b>	Pavilion 3
	<b>Outpatient treatment regimens: Impact on an aging myeloma patient population</b> <i>Co-chairs: Edvan Crusoe and Rakesh Popat</i>	
8:00-8:05	Opening Remarks	Rakesh Popat
8:05-8:15	New and emerging outpatient therapies for the treatment of RRMM: potential impact on the aging myeloma patient population	Suzanne Lentzsch
8:15-8:25	Efficacy of BCMA-targeting agents in early RRMM - a new era?	Adam Cohen
8:25-8:35	Optimizing benefit-risk and minimizing impact on quality of life with BCMA-targeting agents in an outpatient setting	Meletios Dimopoulos
8:35-8:45	Panel discussion: Practical considerations around successfully utilizing BCMA-targeting agents in elderly patients in the real-world – access, eligibility, administration and convenience	
8:45-8:55	Audience Q&A	Edvan Crusoe
8:55-9:00	Closing remarks	
9:00-10:30	<b>HIGH RISK DISEASE</b> <b>P D V</b>	Pavilion 3
	<i>Chair: Simon Harrison, Co-chair: Faith Davies</i>	
9:00-9:10	New classification for identifying HR Myeloma based on cytogenetic abnormalities	Jill Corre
9:10-9:20	Other factors for identification of high risk beyond cytogenetic	Wee Joo Chng
9:20-9:30	How to characterize and manage the functional high risk Myeloma	Martin Kaiser
9:30-9:40	Management of HR Disease--Can change to Clinical Trials in HR disease	Katja Weisel
9:40-10:00	Future Directions and Challenges	Faith Davies
10:00-10:30	Round Table discussion	Session faculty + Angelo Maiolino
10:30-11:00	<b>BREAK</b>	Exhibit Hall, Pavilion 3

11:00-12:30	<b>INDUSTRY SYMPOSIUM SUPPORTED BY JANSSEN</b> P D V	Pavilion 3
	<b>Moving T Cell Directed Therapies to Earlier Lines</b> <i>Chair: Jayr Schmidt</i>	
11:00-11:20	Immunotherapies - Improving Multiple Myeloma treatment	Jayr Schmidt
11:20-11:35	Redefining RRMM treatment with CAR-T cell therapy	Susan Bal
11:35-11:55	One size does not fit all: personalizing treatment approaches beyond frontline	Cesar Rodriguez
11:55-12:15	T-cell Directed Therapies: which one to choose first and why? Debate with the Experts	Rahul Banerjee
12:15-12:25	Q&A	
12:25-12:30	In Summary: How to achieve the best outcomes in this new era of treatment?	Jayr Schmidt
12:30-13:30	<b>LUNCH AND POSTERS</b>	Exhibit Hall, Pavilion 3
13:30-14:30	<b>WALDENSTROM AWARD</b> P D V	Pavilion 3
14:30-15:30	<b>IMS/EHA SYMPOSIUM: CURRENT AND FUTURE GUIDELINES</b> P D V <i>Co-chairs: Philippe Moreau and Pieter Sonneveld</i>	Pavilion 3
14:30-14:45	American Perspective	Luciano Costa
14:45-15:00	European Perspective	Paula Rodriguez-Otero
15:00-15:30	Round Table discussion	Thomas Martin and Michel Delforge
15:30-16:00	<b>BREAK</b>	
16:00-17:30	<b>RELAPSED: TREATMENTS OUTSIDE OF IMMUNOTHERAPY</b> P D V <i>Chair: Vania Hungria, Co-chair: Keith Stewart</i>	Pavilion 3
16:00-16:10	Genomic Evolution at the Time of Relapse	Mehmet Samur
16:10-16:20	Treating Relapsed MM outside of use of TC redirected Therapies	P. Joy Ho
16:20-16:30	Targeted therapies in RR MM: BCL2, BRAF, MEK, MMSET	Marc Raab
16:30-16:40	Treatment of RRMM in resource restricted regions	Hang Quach
16:40-17:00	Future directions and challenges	Keith Stewart
17:00-17:30	Round Table discussion	Session faculty + Pankaj Malhotra
17:30-18:30	<b>ABSTRACT SESSION 3</b> P D <i>Co-chair: Charlotte Pawlyn and Andrzej Jakubowiak</i>	101 A1-A2
17:30-18:30	<b>ABSTRACT SESSION 4</b> P D <i>Co-chair: Nicola Giuliani and Steven Treon</i>	101 B1-B2

# Friday, September 27, 2024

7:00-8:00	<b>MEET THE EXPERT</b> <b>P</b>	
203C	Use of Bispecifics and CAR T cells in South America	Jesus Berdeja and Natalia Schütz
204A	Supportive care in the setting of TCR	Surbhi Sidana and Hira Mian
204B	Myeloma defining events: renal failure and bone disease	Ramon Garcia Sanz and Evangelos Terpos
204C	Waldenstrom's and other plasma cell disorders	Jorge Castillo and Prashant Kapoor
8:00-9:00	<b>INDUSTRY SYMPOSIUM SUPPORTED BY SANOFI</b> <b>P D V</b>	Pavilion 3
	<b>Beyond a one-size-fits-all approach: Personalizing therapy in newly diagnosed multiple myeloma</b>	
	<i>Chair: Thomas Martin</i>	
8:00-8:05	Introduction	Thomas Martin
8:05-8:20	Tailored to fit: New approaches in transplant-ineligible NDMM	Xavier Leleu
8:20-8:35	Made to measure: Choosing the optimal regimen in transplant-eligible NDMM	Elias Mai
8:35-8:55	What is the best fit? Anti-CD38-VRd quads or anti-CD38-KRd quads as a new standard of care in NDMM	Thomas Martin and Lisa Leyboldt
8:55-9:00	Q&A	
9:00-10:00	<b>ABSTRACT SESSION 5</b> <b>P D</b>	101 A1-A2
	<i>Co-chairs: Meral Beksac and Michael O'Dwyer</i>	
9:00-10:00	<b>ABSTRACT SESSION 6</b> <b>P D</b>	101 B1-B2
	<i>Co-chairs: Manoj Bhasin and Francesco Maura</i>	
10:00-10:30	<b>BREAK</b>	Exhibit Hall, Pavilion 3
10:30-12:00	<b>IMMUNOTHERAPY</b> <b>P D V</b>	Pavilion 3
	<i>Chair: Noopur Raje, Co-chair: Nikhil Munshi</i>	
10:30-10:40	BCMA/GPRC5D/FcRH5 – CARs/BsAbs – Clinical Update	Ajai Chari
10:40-10:50	Choice of TCR and How to sequence?	Paula Rodriguez-Otero
10:50-11:00	Mechanisms of resistance to CAR-T and BsAbs	Paola Neri
11:00-11:10	Strategies to overcome the T-cell exhaustion	Hermann Einsele
11:10-11:30	Future Directions and Challenges	Nikhil Munshi
11:30-12:00	Round Table discussion	Session faculty + Niels van de Donk

12:00-13:00	<b>LUNCH AND POSTERS</b>	Exhibit Hall, Pavilion 3
13:00-14:00	<b>RINEY SESSION</b> <b>P D V</b> <i>Co-chairs: Kenneth Anderson and Nikhil Munshi</i>	Pavilion 3
13:00-13:15	Single cell dissection of autologous apheresis products to predict successful manufacturing, safe application and response to chimeric antigen receptor T-cells in newly diagnosed and relapsed myeloma	Maximilian Merz
13:15 - 13:20	Q&A	
13:20-13:35	Modeling, unraveling, and beating acquired resistance to BCMA and GPRC5D targeted agents in multiple myeloma	Jose Martinez-Climent
13:35-13:40	Q&A	
13:40-13:47	Immune cell contribution to drug-resistance in multiple myeloma	Lucia Chen
13:47-13:50	Q&A	
13:50-13:57	Investigating CREB1 signaling as a novel therapeutic target in multiple myeloma	Sara Taranto
13:57-14:00	Q&A	
14:00-16:00	<b>PLENARY SESSION</b> <b>P D V</b> <i>Co-chairs: Leif Bergsagel and Kwee Yong</i>	Pavilion 3
16:00-16:30	<b>BREAK</b>	
16:30-17:30	<b>MOVING THE PATHS TO APPROVAL: REGULATORY CONSIDERATIONS</b> <b>P D V</b> <i>Co-chairs: Thierry Facon and Nikhil Munshi</i>	Pavilion 3
	US	Nicole Gormley and Bindu Kanapuru
	Europe	Edward Laane and Michal Zwiewka
	Discussion	
17:30-18:30	<b>ABSTRACT SESSION 7</b> <b>P D</b> <i>Co-chairs: Tanya Wildes and Javier de la Rubia</i>	101 A1-A2
17:30-18:30	<b>ABSTRACT SESSION 8</b> <b>P D</b> <i>Co-chairs: Jens Hillengass and Andrew Spencer</i>	101 B1-B2
18:30-19:30	<b>POSTER SESSION</b> <b>P</b> <i>Discussants: Noa Biran, Efstathios Kastritis, Adam Sperling, Lugui Qiu</i>	Exhibit Hall, Pavilion 3

# Saturday, September 28, 2024

7:00-8:00	<b>MEET THE EXPERT</b> <b>P</b>	
203C	Career in Basic Science	Mala Shanmugam and Marta Chesi
204A	Career in Translational Research	Jens Lohr and Lawrence Boise
204B	Career as a Clinical Trialist	Aurore Perrot and Karthik Ramasamy
204C	Women in Science	Mariateresa Fulciniti and Angela Dispenzieri
8:00-9:00	<b>INDUSTRY SYMPOSIUM SUPPORTED BY PFIZER*</b> <b>P D V</b>	Pavilion 3
	<b>Transforming Therapy for Patients with Relapsed Multiple Myeloma: Era of BsAb</b>	
	<i>Chair: Mohamad Mohty</i>	
8:00-8:05	Welcome and intro Keep it real: patient demographics in novel immune oncology therapies trials	Mohamad Mohty
8:05-8:15	From conception to application: tracing the journey of BsAb into clinic	Donna Reece
8:15-8:25	Efficacy of BsAb on minorities: Black and AA patients' inclusion on clinical trials	Craig Cole
8:25-8:35	How to treat RRMM with BsAb therapies	Cyrille Touzeau
8:35-9:00	Debate/discussion: How novel BsAb therapies are used in community?	
	<i>*This session is intended for healthcare professionals only.</i>	
9:00-10:00	<b>EMERGING TARGETS IN DRUG THERAPIES</b> <b>P D V</b>	Pavilion 3
	<i>Co-chairs: Sundar Jagannath and Robert Orloszki</i>	
9:00-9:08	Beyond Bispecifics: The promise of TriSpecifics in RRMM	Jordan Schecter
9:08-9:12	Audience Q&A	
9:12-9:20	Optimizing BCMA targeting with an ADC	Joanna Opalinska
9:20-9:24	Audience Q&A	
9:24-9:32	Harnessing protein degradation and novel combinations to address emerging mechanisms of resistance	Nathan Martin
9:32-9:36	Audience Q&A	
9:36-9:44	Investigating alternative approaches to harness the immune system in the treatment of multiple myeloma	Zandra Klippel
9:44-9:48	Audience Q&A	
9:48-9:56	MRD Negativity in Myeloma: A New Goal of Therapy?	Isabel Perez Cruz
9:56-10:00	Audience Q&A	

10:00-11:00	<b>ABSTRACT SESSION 9</b> <b>P D</b> <i>Co-chairs: Al Garfall and Enrique Ocio</i>	101 A1-A2
10:00-11:00	<b>ABSTRACT SESSION 10</b> <b>P D</b> <i>Co-chairs: Raphael Szalat and Gareth Morgan</i>	101 B1-B2
11:00-11:15	<b>BREAK</b>	Exhibit Hall, Pavilion 3
11:15-12:15	<b>ABSTRACT SESSION 11</b> <b>P D</b> <i>Co-chairs: Samir Parekh and Brian Walker</i>	101 A1-A2
11:15-12:15	<b>ABSTRACT SESSION 12</b> <b>P D</b> <i>Co-chairs: Constantine Mitsiades and Damian Green</i>	101 B1-B2
12:15-13:45	<b>NOVEL BIOMARKERS-PERSONALIZING THERAPY IN MYELOMA</b> <b>P D V</b> <i>Chair: Kenneth Anderson, Co-chair: Shaji Kumar</i>	Pavilion 3
12:15-12:25	MRD as a biomarker for treatment decisions	Saad Usmani
12:25-12:35	Novel biomarkers in Myeloma: CTCs and cfDNA	Bruno Paiva
12:35-12:45	Genetic and epigenetic markers for drug selection	Suzanne Trudel
12:45-12:55	Biomarker strategy for minimizing toxicity	Ashley Rosko
12:55-13:15	Future Directions and Challenges	Shaji Kumar
13:15-13:45	Round Table discussion	Session faculty + Noemi Puig
13:45-14:00	<b>CLOSING CEREMONIES</b> <b>P D V</b>	Pavilion 3



The IMS gratefully acknowledges the following organizations for their sponsorship of the 21st IMS Annual Meeting:

TITANIUM LEVEL



PLATINUM LEVEL



GOLD LEVEL



BRONZE LEVEL

